177 related articles for article (PubMed ID: 30474444)
21. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
Noonan A; Pawlik TM
Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
[No Abstract] [Full Text] [Related]
22. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing.
Tonon F; Zennaro C; Dapas B; Carraro M; Mariotti M; Grassi G
Int J Pharm; 2016 Dec; 515(1-2):583-591. PubMed ID: 27989824
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
24. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma.
Song MJ
World J Gastroenterol; 2015 Apr; 21(13):3843-9. PubMed ID: 25852268
[TBL] [Abstract][Full Text] [Related]
25. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Huang CC; Liang PC; Lin ZZ
Asia Pac J Clin Oncol; 2010 Jun; 6(2):80-8. PubMed ID: 20565419
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
27. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
28. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition for the treatment of glioblastoma.
Roth P; Mason WP; Richardson PG; Weller M
Expert Opin Investig Drugs; 2020 Oct; 29(10):1133-1141. PubMed ID: 32746640
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
32. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
33. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
34. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Guan YS; He Q
Expert Opin Pharmacother; 2011 Feb; 12(2):303-13. PubMed ID: 21226640
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
[TBL] [Abstract][Full Text] [Related]
37. An update on clinical trials in the treatment of advanced hepatocellular carcinoma.
Lee JK; Abou-Alfa GK
J Clin Gastroenterol; 2013 Jul; 47 Suppl():S16-9. PubMed ID: 23751800
[TBL] [Abstract][Full Text] [Related]
38. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
39. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
40. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]